MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$236,790K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Stock-based compensation expense
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Purchases of investments
Other assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-284,302
-320,622
-246,507
-212,830
Depreciation and amortization
3,002
2,947
7,497
3,064
Stock-based compensation expense
41,241
37,964
35,997
35,306
Amortization of operating lease right-of-use assets
2,924
2,907
2,303
2,133
Net accretion of discounts on investments
1,182
3,112
2,764
2,264
Unrealized foreign exchange loss (gain)
-5,173
-2,201
1,655
789
Prepaid expenses and other current assets
-13,672
8,743
9,549
-915
Operating lease right-of-use assets
0
0
34,796
0
Other assets
52,949
16,876
11,539
11,316
Operating lease liabilities
-851
-1,285
33,137
-1,401
Accounts payable
31,554
-269
21,667
17,877
Accrued compensation
5,866
-15,018
6,226
5,948
Accrued contract manufacturing expenses
-2,816
54,852
-32,145
19,987
Accrued expenses
6,197
-15,571
7,296
65
Net cash used in operating activities
-232,471
-280,625
-224,832
-143,305
Purchases of property and equipment
4,319
2,107
2,654
3,824
Purchases of manufacturing facility build-out and equipment construction-in-progress
255
12,687
5,767
8,222
Purchases of investments
268,677
584,129
292,649
255,315
Maturities of investments
398,464
340,631
347,972
350,200
Sales of investments
22,506
24,882
68,223
38,331
Net cash (used in) provided by investing activities
147,719
-233,410
115,125
121,170
Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs
-
-
0
-
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs
-
-
0
0
Proceeds from issuance of shares through employee equity incentive plans
7,761
9,032
3,415
306
Proceeds from issuance of common stock from follow-on offering, net of issuance costs
0
601,846
-
0
Taxes paid related to the net share settlement of equity awards
2,060
9,295
1,007
3,977
Net cash provided by financing activities
5,701
601,583
2,408
-3,671
Effect of exchange rate changes on cash and cash equivalents
1,397
-664
176
291
Net increase (decrease) in cash, cash equivalents and restricted cash
-77,654
86,884
-107,123
-25,515
Cash, cash equivalents and restricted cash, beginning of period
262,309
175,425
282,548
389,195
Cash, cash equivalents and restricted cash, end of period
184,655
-
-
-
Cash and cash equivalents
183,190
-
-
-
Restricted cash
1,465
-
-
-
Cash, cash equivalents and restricted cash
184,655
262,309
175,425
282,548
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of investments
$398,464K
(-52.16%↓ Y/Y)
Proceeds from issuance of
shares through...
$7,761K
(-16.40%↓ Y/Y)
Sales of investments
$22,506K
(-66.97%↓ Y/Y)
Net cash (used in)
provided by investing...
$147,719K
(-26.53%↓ Y/Y)
Net cash provided by
financing activities
$5,701K
(73.97%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$1,397K
(-29.16%↓ Y/Y)
Canceled cashflow
$273,251K
Canceled cashflow
$2,060K
Net increase
(decrease) in cash, cash...
-$77,654K
(4.29%↑ Y/Y)
Canceled cashflow
$154,817K
Stock-based compensation
expense
$41,241K
(-38.94%↓ Y/Y)
Accounts payable
$31,554K
(260.68%↑ Y/Y)
Prepaid expenses and
other current assets
-$13,672K
(-267.43%↓ Y/Y)
Accrued expenses
$6,197K
(544.55%↑ Y/Y)
Accrued compensation
$5,866K
(159.42%↑ Y/Y)
Unrealized foreign
exchange loss (gain)
-$5,173K
(-116.00%↓ Y/Y)
Depreciation and
amortization
$3,002K
(-48.55%↓ Y/Y)
Amortization of operating
lease right-of-use...
$2,924K
(-27.41%↓ Y/Y)
Purchases of investments
$268,677K
(-59.51%↓ Y/Y)
Purchases of property and
equipment
$4,319K
(-40.30%↓ Y/Y)
Purchases of
manufacturing facility...
$255K
(-99.13%↓ Y/Y)
Taxes paid related to
the net share...
$2,060K
(-65.71%↓ Y/Y)
Net cash used in
operating activities
-$232,471K
(19.12%↑ Y/Y)
Canceled cashflow
$109,629K
Net loss
-$284,302K
(7.48%↑ Y/Y)
Other assets
$52,949K
(210.90%↑ Y/Y)
Accrued contract
manufacturing expenses
-$2,816K
(-106.52%↓ Y/Y)
Net accretion of
discounts on investments
$1,182K
(-87.43%↓ Y/Y)
Operating lease
liabilities
-$851K
(-105.81%↓ Y/Y)
Buy us a coffee
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)